REPRO-MED Systems (KRMD) AI Stock Analysis

• Market Cap: $161.95M
• Dividend Yield: N/A
• Average Volume (3M): 351.68K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: 19.65%
• EPS Growth: 60.28%
• Country: US
• Employees: 80
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.00
• Shares Outstanding: 46,140,995
• 10 Day Avg. Volume: 144,956
• 30 Day Avg. Volume: 351,679
• PEG Ratio: -3.37
• Price to Book (P/B): 8.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -75.77
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 0.99
• Enterprise Value/Gross Profit: 5.86
• Enterprise Value/Ebitda: -5.78
• 1Y Price Target: $4.83
• Price Target Upside: 37.61% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 62 Neutral
• Price Target: $3.50 ▼(-0.28%Downside)

The overall score reflects a mixed outlook: strong earnings call performance and technical stability are offset by weak financial performance and valuation. Addressing profitability and enhancing cash flow are vital for improving the stock's potential.

Positive Factors

Product Innovation

The new product initiative is focused on an easier-to-use and more comfortable pump and disposable infusion set.

Revenue Growth

KRMD delivered a strong quarter as it beat on revenue and margin expectations, seeing material outperformance in its OUS markets even taking distributor stocking into account.

Negative Factors

Competitive Pressures

There is wariness of the potential for competitive pressures to expand going forward.

Valuation Concerns

KORU is valued at approximately twice the valuation shares traded at a year ago due to exceptional management of cash and significant progress with future growth opportunities.

REPRO-MED Systems Business Overview & Revenue Model

Company Description

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.

How the Company Makes Money

REPRO-MED Systems generates revenue primarily through the sale of its medical devices and related accessories. The company's key revenue streams include the sale of the FREEDOM System, which consists of durable infusion pumps, administration sets, and needle sets. The company also earns from providing customer support and training for the effective use of its products. Significant factors contributing to its earnings include partnerships with pharmaceutical companies and healthcare providers, facilitating the integration of its infusion systems into broader treatment regimens. Additionally, the company's focus on addressing unmet needs in chronic disease management supports its market position and revenue growth.

REPRO-MED Systems Financial Statement Overview

Summary

REPRO-MED Systems shows revenue growth but struggles with profitability due to negative EBIT and net profit margins. The balance sheet is stable with a moderate debt-to-equity ratio and a solid equity base, yet consistent losses and negative cash flows highlight operational inefficiencies.

Income Statement

The company shows a consistent growth trajectory in revenue with a 5% increase from the previous period to TTM. However, it struggles with profitability as evidenced by negative EBIT and net profit margins, indicating operational inefficiencies and high costs relative to revenue. The gross profit margin remains healthy, suggesting some control over direct costs.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio of 0.22, indicating prudent leverage. However, the return on equity is negative due to consistent net losses, which is a concern. The equity ratio of 60% indicates a solid capital structure with more equity financing, providing some financial stability.

Cash Flow

Cash flow analysis reveals challenges, as the company has negative operating cash flow and free cash flow, indicating potential liquidity issues. The free cash flow growth rate improved slightly, but remains negative, highlighting ongoing cash management challenges. The operating cash flow to net income ratio is unfavorable due to persistent losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.65M	28.52M	27.90M	23.49M	24.18M
Gross Profit	21.33M	16.71M	15.37M	13.77M	14.94M
EBITDA	-5.56M	-9.40M	-10.19M	-6.57M	1.61M
Net Income	-6.07M	-13.74M	-8.66M	-4.56M	-1.21M
Balance Sheet
Total Assets	27.22M	28.46M	42.33M	41.29M	39.92M
Cash, Cash Equivalents and Short-Term Investments	9.58M	11.48M	17.41M	25.33M	27.32M
Total Debt	3.99M	4.45M	4.93M	604.14K	239.49K
Total Liabilities	10.40M	8.11M	11.01M	4.79M	3.76M
Stockholders Equity	16.81M	20.35M	31.33M	36.50M	36.16M
Cash Flow
Free Cash Flow	-1.62M	-5.71M	-8.21M	-4.69M	-1.80M
Operating Cash Flow	-319.72K	-4.89M	-5.40M	-4.32M	-743.32K
Investing Cash Flow	-1.33M	-814.60K	-2.80M	-366.17K	-1.04M
Financing Cash Flow	-248.53K	-218.87K	279.49K	2.71M	23.22M

REPRO-MED Systems Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KRMD, the sentiment is Positive. The current price of 3.51 is above the 20-day moving average (MA) of 3.50, above the 50-day MA of 3.23, and above the 200-day MA of 3.29, indicating a bullish trend. The MACD of 0.04 indicates Positive momentum. The RSI at 54.45 is Neutral, neither overbought nor oversold. The STOCH value of 71.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KRMD.

REPRO-MED Systems Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	74 Outperform	$188.59M	15.40	10.39%	2.09%	-16.64%	―
INFU	68 Neutral	$125.01M	40.60	5.94%	―	7.98%	3304.55%
KRMD	62 Neutral	$161.95M	―	-29.87%	―	19.65%	60.28%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
RVP	52 Neutral	$21.11M	―	-25.89%	―	-16.05%	-195.28%
MLSS	40 Underperform	$46.69M	―	-88.36%	―	-9.13%	30.04%
MBOT	―	$99.68M	―	-66.48%	―	―	―

REPRO-MED Systems Corporate Events

REPRO-MED Systems Holds Annual Shareholder Meeting

On May 14, 2025, REPRO-MED Systems held its Annual Meeting of Shareholders where key decisions were made regarding the company’s governance and financial oversight. Shareholders elected the proposed nominees to the board of directors, approved executive compensation on an advisory basis, and ratified the appointment of Cherry Bekaert LLP as the independent registered public accountants for the 2025 fiscal year.

The most recent analyst rating on (KRMD) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.